190 related articles for article (PubMed ID: 3877790)
1. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution.
Gaynor ER; Ultmann JE; Golomb HM; Sweet DL
J Clin Oncol; 1985 Dec; 3(12):1596-604. PubMed ID: 3877790
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
3. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
Skarin AT; Canellos GP; Rosenthal DS; Case DC; MacIntyre JM; Pinkus GS; Moloney WC; Frei E
J Clin Oncol; 1983 Feb; 1(2):91-8. PubMed ID: 6199472
[TBL] [Abstract][Full Text] [Related]
4. Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen.
Baer MR; Stein RS; Greer JP; Wolff SN; Hainsworth JD; Flexner JM
Cancer Treat Rep; 1986 Jun; 70(6):785-7. PubMed ID: 3488125
[TBL] [Abstract][Full Text] [Related]
5. NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.
Koziner B; Sklaroff R; Little C; Labriola D; Thaler HT; Straus DJ; Young CW; Nisce LZ; Oettgen H; Lee BJ
Cancer; 1984 Jun; 53(12):2592-600. PubMed ID: 6547072
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
[TBL] [Abstract][Full Text] [Related]
7. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma.
Sweet DL; Golomb HM; Ultmann JE; Miller JB; Stein RS; Lester EP; Mintz U; Bitran JD; Streuli RA; Daly K; Roth NO
Ann Intern Med; 1980 Jun; 92(6):785-90. PubMed ID: 6992679
[TBL] [Abstract][Full Text] [Related]
9. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the Lukes and Collins classification in patient treated with COMLA.
Sweet DL; Collins RD; Stein RS; Ultmann JE
Cancer Treat Rep; 1982 May; 66(5):1107-11. PubMed ID: 7044531
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of patients with localized diffuse histiocytic lymphoma.
Vokes EE; Ultmann JE; Golomb HM; Gaynor ER; Ferguson DJ; Griem ML; Oleske D
J Clin Oncol; 1985 Oct; 3(10):1309-17. PubMed ID: 3900300
[TBL] [Abstract][Full Text] [Related]
12. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
13. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
15. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prognosis of orbital non-Hodgkin's lymphomas.
Platanias LC; Putterman AM; Vijayakumar S; Recant W; Weichselbaum RR; Bitran JD
Am J Clin Oncol; 1992 Feb; 15(1):79-83. PubMed ID: 1372464
[TBL] [Abstract][Full Text] [Related]
17. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
[TBL] [Abstract][Full Text] [Related]
18. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
[TBL] [Abstract][Full Text] [Related]
19. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP
J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615
[TBL] [Abstract][Full Text] [Related]
20. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
